LTS to support Micron Biomedical as strategic CDMO partner to scale up Micron´s Microarray Patch technology

Andernach – LTS, a leading pharmaceutical technology company, announced today that it will support Micron Biomedical, Inc. (“Micron”) as selected CDMO partner in the manufacturing scale-up of Micron´s Microarray Patch (“MAP“) technology. Micron has recently received a grant of $23.6 Million from the Bill & Melinda Gates Foundation to design, build, and install a manufacturing line capable of producing millions of microarray patches annually for vaccination against Measle/Rubella and other global health diseases. A part of this grant from the Bill & Melinda Gates Foundation will be used to set up the GMP-compliant automated manufacturing line at LTS. This collaboration between Micron and LTS builds on the Technical Transfer and Scale-up Agreement signed in November 2022. The engineering and production capabilities of LTS, as well as its proven track-record to bring new innovative drug-delivery technologies to the market, will support Micron’s mission to bring life-saving vaccination to Low-and Middle-Income Countries (LMIC). As part of the collaboration agreement, LTS will invest into a dedicated aseptic manufacturing campus.

Micron Biomedical, located in Atlanta, GA, USA, is the leader in dissolvable microarray-based, drug and vaccine administration technology. Micron Biomedical is a clinical-stage life science company on a rapid path to commercializing its proprietary dissolvable, microarray technology. Micron’s technology is designed to improve access and achieve better health outcomes globally through injection-free, painless, and simple and/or self-administration of drugs and vaccines, and by eliminating or reducing the need for cold chain transport and storage, enhancing safety and efficacy, and improving patient compliance. Micron partners with and/or receives funding from private and public pharmaceutical and biotech companies, the Bill & Melinda Gates Foundation, the Centers for Disease Control and Prevention (CDC), PATH and the Georgia Research Alliance.

Bas van Buijtenen, CEO of LTS, said: “We congratulate Micron on the award of the grant by the Bill & Melinda Gates Foundation, and we are excited to continue our vision, dedication and commitment to improve people’s lives, specifically those mired in inequality, by supporting the development of cutting-edge technology. This exciting project aligns perfectly with the LTS Mission of We Care, We Create, We Deliver: we couldn’t be more thrilled to have an opportunity to make a contribution.”

„Micron is excited to leverage its partnership with LTS to establish large-scale, automated manufacturing capacity to further establish Micron‘s position as the leader in dissolvable microarray-based drug and vaccine technology,” commented Steven Damon, CEO of Micron. “We are grateful for the continued support of the Bill & Melinda Gates Foundation.”

About LTS
We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China.

Contact
Dr Iris Schnitzler
iris.schnitzler@ltslohmann.com